Abeona Therapeutics (NASDAQ:ABEO) Raised to “Hold” at StockNews.com

Abeona Therapeutics (NASDAQ:ABEO) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

Other equities research analysts have also issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research note on Monday. Oppenheimer began coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price target for the company. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $17.50.

Abeona Therapeutics Stock Performance

NASDAQ ABEO opened at $5.00 on Monday. The business has a 50 day moving average price of $5.43 and a 200 day moving average price of $5.82. The company has a market capitalization of $217.36 million, a P/E ratio of -1.86 and a beta of 1.79. Abeona Therapeutics has a 1-year low of $3.05 and a 1-year high of $8.45. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12.

Abeona Therapeutics (NASDAQ:ABEO) last posted its earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.19. Sell-side analysts expect that Abeona Therapeutics will post -1.16 EPS for the current fiscal year.

Institutional Trading of Abeona Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Abeona Therapeutics by 20.1% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock worth $21,736,000 after purchasing an additional 652,366 shares during the last quarter. Western Standard LLC boosted its stake in Abeona Therapeutics by 22.8% in the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock worth $11,610,000 after buying an additional 386,321 shares during the last quarter. 683 Capital Management LLC boosted its stake in Abeona Therapeutics by 17.3% in the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock worth $4,411,000 after buying an additional 116,845 shares during the last quarter. Citigroup Inc. grew its holdings in Abeona Therapeutics by 10.1% in the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock valued at $3,897,000 after buying an additional 56,332 shares during the period. Finally, Geode Capital Management LLC increased its stake in shares of Abeona Therapeutics by 21.7% during the 3rd quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock valued at $2,942,000 after acquiring an additional 83,050 shares during the last quarter. 80.56% of the stock is owned by hedge funds and other institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.